Overview Cardiovascular & Renal: Recent developments in renin inhibitors: part 1

References

• NAGAMI T, MIZUNO K, NAKAMARU M, PANDEY KN, NARUSE M, NARUSE K, MISONO K, OKAMURA T, KAWA-MURA M, HIGASHIMORI K: The renin-angiotenshi sys-tem: an overview of its intracellular fraction. Cardiovasc. Drugs Tber. (1988) 2:453–458.
   PubMedGoogle Scholar
• BRUNNER HR, WAEBER B, NUSSBERGER J: Renin secre-tion responsiveness: understanding the efficacy of renin-angiotensin inhibition. Kidney Mt. (1988) 34 (suppl 26):S80–S85.
   Google Scholar
• DZAU VJ: Circulation versus local renin-angiotensinsystem in cardiovascular homeostasis. Circulation (1988) 77 (suppl 1):1/4–1/13.
   Google Scholar
• FERRARIO CM: The renin-angiotensin system: impor-tance in physiology and pathology. J. Cardiovasc. Phar-macol. (1990) 15 (suppl 1):S1––S5.
   Google Scholar
• OND MA, CUSHMAN DW: Enzymes of the renin-angiotensin system and their inhibitors. Annu. Rev. Biochem. (1982) 51:283–308.
   PubMedGoogle Scholar
• WYVRATT MJ, PATCHETT AA: Recent developments inthe design of angiotensin-coiwerting enzyme inhibi-tors. Med. Res. Rev. (1985) 5:483–531.
   PubMed Web of Science ®Google Scholar
• GAVRAS H, GAVRAS I: Angiotensin converting enzymeInhibitors. Properties and side effects. Hypertension 1988, 11(3) (suppl 11):37–41.
   Google Scholar
• ZANCHETTI A: Angiotensin-converting enzyme inhibi-tors in essential hypertension. J. Cardiovasc. Pbarmacol. (1987) 9\(suppl 3):S2–5.
   Google Scholar
• KOSTIS JB: Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. Am. J. Hy-pertens. (1989) 2:57–64.
   Google Scholar
• ERDOS EG: Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension (1990) 16:363–370.
   PubMed Web of Science ®Google Scholar
• SLATER E, MERRILL DD, GUESS HA, ROYLANCE J, COOPERWD, INMAN WHW, EWAN PW: Clinical profile of angiodema associated with angiotensin converting-en-zyme inhibition. J. Am. Med. Assoc. (1988) 260:967–970.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS PBMWM, WONG PC, CHIN AT, HERBLIN WF:Non-peptide angiotensin 11 receptor antagonists. TIPS (1991) 12:55–62.
   PubMedGoogle Scholar
• GREENLEE W: Renin inhibitors. J. Med. Res. Rev. (1990)10:173–236.
   PubMed Web of Science ®Google Scholar
• GREENNLEE W: Renin inhibitors. J. Med. Res. Rev. (1987)4:364–374.
   Google Scholar
• WOOD JM, STANTON JL, HOFBAUER KG: Inhibitors ofrenin as potential therapeutic agents. J. Enzyme Inhibi-tion (1987) 1:169–185.
   PubMedGoogle Scholar
• OCAIN TD, ABOU-GHARBIA M: Renin-angiotensin sys-tem (RAS) dependent antihypertensives: L renin inhibi-tors. Drugs of the Future (1991) 16:37–51.
   Google Scholar
• BREIPOHL G, GEIGER R, HENKE S, KLEEMANN H-W, KNOLLE J, RUPPERT D, SCH0LKENS BA, URBACH H, WAGNER A, WEGMANN H: Studies on renin inhibitors. Spec. Pub!. R. Soc. Chem. (1988) 65:101–127.
   Google Scholar
• CORVOL PL, CHAUREAU D, JEUNEMAITRE X, MENARD J:Human renin inhibitor peptides. Hypertension (1990) 16:1–11.
   PubMed Web of Science ®Google Scholar
• KLEINERT HD: Renin inhibitors: discovery and develop-ment. Am. J. Hypertens. (1989) 2:800–808.
   PubMedGoogle Scholar
• KLEINERT HD, BABER WE, STEIN HH: Renin inhibitors. Adv. Pharmacol. (1991) 22:207–250.
   PubMedGoogle Scholar
• SCHECHTER J, BERGER A: On the size of active site inproteases. L Papain. Biochem. Biophys. Res. Comm. (1967) 27:157–162.
   PubMed Web of Science ®Google Scholar
• UMEZAWA H, AOYAGI T, MORISHIMA H et al.: Pepstatina new pepsin inhibitor produced lby Aainotnycetes. J. Anti biot. (1970) 23:259–262.
   Google Scholar
• GROSS F, 1AZAR J, ORTH H: Inhibition of the renin-angiotensinogen reaction by pepstatin. Science (1972) 175:656.
   PubMed Web of Science ®Google Scholar
• MILLER RP, POPER LH, WILSON CW, DE VITO E: Renin inhibition by pepstatin. Biochem. PharmacoL (1972) 21:2941–2944.
   PubMed Web of Science ®Google Scholar
• BOGER J, LOHR NS, ULM EM etal.: Novel renin inhibitors containing the amino acid statine. Nature (1983) 303:2941–2944.
   Google Scholar
• KOKUBO T, UEDA E, FUJIMOTO S etal.: Peptide inhibi- tors of renin-angiotensin system. Nature (1968) 217:456–459.
   Google Scholar
• SKEGGS LT, LENTZ ICE, HAHN JR, HOOCHSTRASSE H: Kinetics of the renin reaction with nine synthetic peptide substrates. J. Exp. Med. (1968) 128:13–34.
   PubMedGoogle Scholar
• SZELKE M, LECKIE B, HALLET A etal.: Potent new inhibi-tors of human renin. Nature (1982) 299:553–557.
   Google Scholar
• SZELKE M, LECKIE BJ, TREE M, BROWN A, GRANT J, HALLETT A, HUGHES M, JONES DM, LEVER AF: A potent new renin inhibitor. In vitro and in vivo studies. Hyper- tension (1982) 4 (suppl5941-69.
   Google Scholar
• WEBB DJ, CUMMING AMM, LECKIE BJ, etal.: Reduction of blood pressure in man with H142. Lancet (1983) 2:1486–1487.
   Google Scholar
• SZELKE M, JONES DM, ATRASH B et al.: Novel transition - state analogue inhibitors of renin. Peptides, structure and function. In: Proceedings °Jibe Eighth American Peptide Symposium (1983). HRUBY V, RICH D (Eds.), Rockford, Illinois, Pierce Chemical Co. 579–582.
   Google Scholar
• THAISRIVONGS S, PALS DT, HARRIS DW, KATI WM, TURNER SR: Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo. j. Med. Chem. (1986) 29:2088–2093.
   PubMedGoogle Scholar
• PLATTNER JJ, MARCOTTE PA, KLEINERT HD, STEIN HH, GREER J, BOLTS G, FUNG AKL, BOPP BA, LULY JR, SHAM HL, KEMPF DJ, ROSENBERG SH, DELLARIA JF, DE B, MERITS I, PERUN TJ: Renin inhibitors. Dipeptkle analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability. J. Med. Chem. (1988) 31:2277–2288.
   Google Scholar
• BÜHLMAYER P, CASELLI A, FUHRER W, GOSCHE R, RASETTI V, MAGER H, STANTON JL, CRISCIONE L, WOOD JM: Synthesis and biological activity of some transition state inhibitors of human renin. J. Med. Chem. (1988) 31:1839–1846.
   PubMed Web of Science ®Google Scholar
• IIZUKA K, KAMIJO T, HARADA H, AKAHANE K, KUBOTAT, UMEYAMA H, ISHIDA T, KISO Y: Orally potent human refill' inhibitors derived from angiotertsinogen transi-tion state: design, synthesis and mode of interaction_ J. Med. Chem. (1990) 33:2707–2714.
   Google Scholar
• KALTENBRONN JS, HUDSPETH JP, LUNNEY EA, MICH-NIEWICZ BM, NICOLAIDES ED, REPINE JT, ROARK WH, STIER MA, TINNEY FJ, WOO PICW, ESSENBURG AD: Renin Inhibitors containing isosteric replacements of the am-ide bond connecting the P3 and P2 sites. J. Med. Chem. (1990) 33:838–845.
   PubMedGoogle Scholar
• KEMPF DJ, DE LARA E, STEIN HM, COHEN J, EGAN DA,PLATTNER JJ: Renin inhibitors based on dipeptide ana-logues. Incorporation of the hydroxyetheylene isostere at the P2/P3 sites. J. Med. Chem. (1990) 33:371–374.
   Google Scholar
• RADDATZ P, JONCZYK A, MINCK K-0, SCHMITGES CJ,SOMBROEK J: Substrate analogue renin inhibitors con-taining replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites. J. Med. Chem. (1991) 34:3267–3280.
   PubMedGoogle Scholar
• SHIBASAICI M, ASANO M, FUKUNAGA Y, USUI T, ICHIHARA M, MURAKAMI Y, NAKANO K, FUJIKURA T: Pharmacologi-cal properties of TM-21095. A potent and highly specific renin inhibitor. Am. J. Hypertens. (1991) 4:932–938.
   PubMedGoogle Scholar
• RIVERO RA, GRENNLEE WJ, PATCHETT AA: Sulfones as peptides bond isosteres. TILL (1991) 39:5263–5264.
   Google Scholar
• BUNDY GL, PALS DT, LAWSON JA, COUCH SJ, LIPTON ME, MAURAGIS MA: Potent renin inhibitory peptides con-taining hydrophilic end groups. J. Med. Chem. (1990) 33:2276–2283.
   PubMedGoogle Scholar
• BOCK MG, DIPARDO RM, EVANS BE, FREIDINGER RM, RITTLE ICE, PAYNE IS, BOGER J, 'WED. IER WE, LAMONT BI, ULM EH, BLAINE EH, SCHORN TW, VEBER DF: Renin Inhibitors containing hydrophths groups. Tetrapeptide with enhanced solubility and nanomolar potency. J. Med. Chem. (1988) 31:1918–1923.
   Google Scholar
• ROSENBERG SH, WOODS KW, SHAM HL, KLEINERT HD,MARTIN DL, STEIN H, COHEN J, EGAN DA, BOPP B, MERITSI, GARREN KW, HOFFMAN DJ, PLATTNER JJ: Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action. J. Med. Chem. (1990) 33:1962–1969.
   PubMedGoogle Scholar
• THAISRIVONGS S, PALS DT, DUCHARME DW, TURNER SR, DEGRAAF GL, LAWSON JA, COUCH SJ, WILLIAMS MV: Retain inhibitory peptides. Incorporation of polar, hy-drophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin-infused rat model and in conscious sodiu.m-de-pleted monkeys. J. Med. Chem. (1991) 34:633–642.
   Google Scholar
• FISCHER JF, HARRISON AW, BUNDY GL, WILKINSON ICE, RUSH BD, RUWART MJ: Peptide to glycopeptide: glyco-sylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. J. Med. Chem. (1991) 34:3140–3143.
   PubMed Web of Science ®Google Scholar
• DELABAYS A, NUSSBERGER J, PORCHET M, etal.: Hemody-namic and huumoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension (1989) 13:941–947.
   Google Scholar
• BURSZTYN M, GARVAS I, LP, BAUER JH, MELBY JC,GAVRAS H: Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. J. Hypertension (1989) 7 (suppl 6):S306–307.
   Google Scholar
• BURSZTYN M, GAVRAS I, TIFFT LP, LUTHER R, BOGER R,GAVRAS H: Effect of a novel renin inhibitor in patients with essential hypertension. J. Cardiovasc. Pharmacol. (1990) 15:493–500.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS NN, NEUTEL JH, GLASSMAN HN, BOGER RS,WEBER MA, LUTHER RR: The hypertensive effect of Increasing doses of enalkiren, a dipeptide renin inhibi-tor, compared with enalaprilat in hypertensive pa-tients. Brit. J. Clin. Pharmacol. (1990) 29:614–615.
   Google Scholar
• NEUTEL JH, ESSINGER I, SMITH DHG, LUTHER RR, WEBER MA: Renin inhibition compared with ACE inhibition in hypertension. Circulation (1989) 80:11-22 (Abstr.)
   Google Scholar
• ANDERSON PW, BOGER RS, LUTHER RR, HSUEH WA: The effect of renin inhibitor A-64662 on blood pressure in patients with essential hypertension. Clin. Res (1989) 37 Abstr. 392A.
   Google Scholar
• BOGER R, MOYSE D, KLEINERT H, GLASSMAN H, CAVANAUGH J, LUTHER RR: Sustained suppression of plasma renin activity (PRA) and blood pressure (BP) following one daily administration of the renin inhibi-tor A-64662 for one week. J. Clin. Pharmacol. (1989) 29 (Abstr. 861).
   Google Scholar
• ANDERSON WP, DO YS, SCHAMBELAN, HORTON R, BO-GER RS, LUTHER RR, HSUEH WA: Effects of renin inhibi-tion in systemic hypertension. Am. J. Cardiol. (1990) 66: 1342–1347.
   PubMedGoogle Scholar
• NEUBERG GW, KUKIN ML, PENN J, MEDINA N, YUSHAK M, PACKER M: Hemodynamie effects of renin inhibition by enalkiren in chronic congestive heart failure. Am. J. Cardiol. (1991) 67:63–66.
   Google Scholar
• CORDERO P, FISHER ND, MOORE TJ, GLEASON R, WIL-LIAMS GH, HOLLENBERG AK: Renal and endocrine re-sponses to a renin inhibitor, enalkiren, in normal humans. Hypertension (1991) 17:510–516.
   PubMed Web of Science ®Google Scholar
• NEUTEL JM, LUTHER RR, BOGER RS, WEBER MA: Immedi-ate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme in-hibitor enalaprilat Am. Heart. J. (1991) 122:1094–1099.
   PubMed Web of Science ®Google Scholar
• JEUNAMAITRE X, MENARD J, NUSSBERGER J, GUYENNE 'IT, BRUNNER HR: Plasma angiotensin, renin and blood pressure during acute renin inhibition by CGP 38560 A In hypertensive patients. Am. J. Hypertens. (1988) 2:819–827.
   Google Scholar
• DE GASPARO M, CUMIN F, NUSSBERGER J, GUYENNE TT,WOOD JM, MENARD J: Pharmacological investigations of a new renin inhibitor in normal sodium restricted volunteers. Brit. J. Clin. Pharmacol. (1989) 27:587–596.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, DELABAYS A, DE GASPARO M et al.: Hetnodynamic and biochemical consequences of renin Inhibition by infusion of CGP 38560 A in normal volun-teers. Hypertension (1989) 13:948–953.
   Google Scholar
• FERRY JJ, LA1UNGS DB, CLOSSON SK, LUDERER JR: Com-parative pharmacokineties of the new renin inhibitor ditekiren in sodium replete and sodium deplete healthy volunteers. ain. Pharmacol. Ther. (1990) 47:157 P11-37 (Abst.).
   Google Scholar
• LUDERER J, FROESCHKE M, WATHEN L, HARRELSON W,BRYAN W, BOKROS j, MOHRLAND S, MET7IFR C: Prelimi-nary human experience with the renin inhibitor ditekiren (D). Clin. Pharmacol. Ther. (1990) 47, 200 P111-84 (Abst).
   Google Scholar
• ABERNETHY DR, WILNER KD, LAZAR JD, WILKES BM: Inhibition of furosemide stimulated plasma renin ac-tivity after oral administration of Cp-80,794. A putative renin inhibitor. din. Pharmacol. Ther. (1990) 47:141.
   Google Scholar
• KOKUBU T, HIWADA K, MURAKAMI E, MUNETA S, KITAMI Y, SALMAN PF: ES-8891 an orally active inhibitor of human refill Hypertension (1990) 15:909–913.
   Google Scholar
• KOKUBU T, FHWADA K, MURAKAMI E, MUNETA S, KITAMI Y, 01ZUMI K, TAKAHAG1 H, KO1KE H: An orally active Inhibitor of human renin, ES-8891. Cardiovasc. Drug Rev. (1991) 9:49–58.
   Google Scholar
• CAMENZIND E, NUSSBERGER J, WAEBER B, VAN BRUM-MELEN P, BRUNNER HR: Oral renin inhibition by Ro 42–5892 reduces plasma anglotensin II levels in man. Hypertension (1989) 14 (Abst. 349).
   Google Scholar
• VAN DEN MEIRACKER AH, ADMIRAAL PJJ, MAN IN'T VELD AJ, DERKX FHM, RITSEMA VAN ECK HJ, MULDAR P, VAN BRUMMELEN P, SCHALEKAMP MNDH: Prolonged blood pressure reduction by orally active renin inhibitor Ro 42-5892 in essential hypertension. Brit. Med. J. (1990) 301:205–210.
   PubMedGoogle Scholar
• CAMENZIND E, NUSSBERGER J, JUILLERAT JL, MUNATO A,FISCHLI W, COASSOLO P, VAN BRUMELEN P, KLEINBLOE-SEM CH, WAEBER B, BRUNNER HR: Effect of the renin response during refill' Inhibition. oral Ro 42–5892 in normal humans. J. Cardiovasc. Pharmacol. (1991) 18:299–307.
   Google Scholar
• DERKX FHM, VAN DEN MEIRACICER AH, FISCHLI W, AD-MIRAAL PJJ, MAN IN'T VELD AJ, VAN BRUMMELEN P, SCHALEICAMP MADH: Non-parallel effects of renin in-hibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. Am. J. Hypertension (1991) 4:602–609.
   PubMedGoogle Scholar
• KIOWSKI W, LINDER L, KLEINBLOESEM C, VAN BRUMME-LEN P, BUHLER FR: Blood pressure control by the renin-angiotensin system in normotensive subjects. Circulation (1992) 85:1–8.
   PubMed Web of Science ®Google Scholar
• DOIG JK, MACFADYEN RJ, MEREDITH PA, FISCHLI W, REIDJL: Neurohorrnonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-repleted man. J. Cardiovasc. Pharrna-col. (1992) 20:875–880.
   PubMedGoogle Scholar
• CLOZEL J-P, FISCHLI W: Discovery of remikiren as thefirst orally active renin inhibitor. Arzneim.-Forsch /drug Res. (1993) 43:260–263.
   PubMedGoogle Scholar
• DENOLLE T, LUO P, GUYENE TT, CAZAUBON C, SISSMANN J, CORVOL P, MENARD J: Acute effects of a pseudo-tetrapeptide as renin inhibitor and blood pressure and renin-angiotensin system of sodium-repleted and so-dium-depleted hypertensive patients. Arzneim.-Forsch./Drug Res. (1993) 43(1):255–259.
   PubMedGoogle Scholar
• OGIHARA T, HIGAKI J, NAGANO M, HIGASH1MORI K, MASUO K, MIKAMI H: A novel human renin inhibitor with a clinically applicable bioavailabilhy, FK906. Hy-pertension (1992) 20(3):Abst P16.
   Google Scholar
• KLEEMANN HW, HEITSCH H, HENNING R, KRAMER W, KOCHER W, LERCH U, LINZ W, NICKEL WU, RUPPERT D, UR13ACH H, et al.: Renin inhibitory pentols showing Improved enteral bioavaiLability. J. Med. Chem. (1992) 35:559–567.
   Google Scholar
• ASHTON WT, CANTON CL, TOLMAN RL, GREENLEE WJ, LYNCH RJ, SCHORN TW, STROUSE JF, SIEGL PK: Inhibitors of human renin with C-termini derived from amides and esters of a-mercaptoalkanoic acids. J. Med. Chem. (1992) 35:2772–2781.
   PubMedGoogle Scholar
• RADDATZ P, JONCZYK A, MINCK KO, RIPPMANN F, SCHIT- TENHELM C, SCHMITGES CJ: Renin inhibitors containing new Pi- P1' dipeptide minietics with heterocycles in El'. J. Med. Chem. (1992) 35:3525–3526.
   PubMedGoogle Scholar
• ASHTON WT, CANTONE CL, MEURER LC, TOLMON RI, GREENLEE WJ, PATCHETT AA, LYNCH RJ, SCHORN TW, STROUSE JF, SIEGL PK: Renin inhibitors containing C-termini derived from mercaptoheterocycles. J. Med. Chem. (1992) 35:2103–2112.
   PubMedGoogle Scholar
• PATT WC, HAMILTON HW, TAYLOR MD, RYAN MJ, TAY-LOR DG JR, CONNOLLY CJ, DOHERTY AM, ICLUTCHKO SR, SIRCAR I, STEINBAUGH BA et al.: Structure-activity rela-tionship of a series of 2-amino-4-thinzole-containing renin inhibitors. J. Med. Chem. (1992) 35:2562–2572.
   PubMed Web of Science ®Google Scholar
• DOHERTY AM, SIRCAR I, KORNBERG BE, QUIN J, WINTERSRT, KALTENBRONN JS, TAYLOR MD, BATLEY BL, RAPUN-DALO SR, RYAN MJ et al.: Design and synthesis of potent, selective, and orally active fluorine-containing renin Inhibitors. J. Med. Chem. (1992) 35:2–14.
   PubMed Web of Science ®Google Scholar
• a. REPINE JT, KALTENBRONN JS, DOHERTY AM, HAMBY JM, HIMMEISBACH RJ, KORNBERG BE, TAYLOR MD, LUNNEY EA, HUMBLET C, RANUNDALO ST et al.: Renin inhibitors containing a-heteroatom amino acids as P2 residues. J Med. Chem. (1992) 35:1032–1042.
   PubMedGoogle Scholar
• b. DOHERTY AM, KALTENBRONN JS, HUDSPETH JP, REPINE JT, ROARK WH, SIRCAR I, TINNEY FJ, CONNOLY CJ, HODGES JC, TAYLOR MD, BATLEY BL, RYAN MJ, ESSEN-BURG AD, RAPUNDALO ST, WEISHARR RE, HUMBLET C, LUNNEY EA: New inhibitors of human renin that con-tain novel replacement at the P2 site. J. Med. Chem. (1991) 34:1258–1271.
   PubMedGoogle Scholar
• c. DELLARIA JF, MART RG, BOPP BA, COHEN J, KLEINHERT HD, LLTLY JR, MERITS I, PLATTNER JJ, STEIN HH: Optimi-zation and fn vivo evaluations of a series of small, potent and specific renin inhibitors containing a novel Leu-Val replacement J. Med. Chem. (1987) 30:2137–2144.
   Google Scholar
• d. THAISRIVONGS S, MAO B, PALS DT, TURNER SR, KROLL LT: Renin inhibitory peptides. A 13-asparyl residue as a replacement for the histidyl residue at the P2 site. J. Med. Chem. (1990) 33:1337–1343.
   Google Scholar
• e. JUPP RA, DUNN BM, JACOBS JW, VLASUK G, ARCURI RE, VERBER DF, PERLOW DS, BOGER J, DE LASZLO S, CHAK-RAVARTY PK, TEN BROEKE J, HANGAUER DG, ONK-DEKYA D, GREENLEE WJ, KAY J: The selectivity of statine-based inhibitors against various human aspartic proteinases. Biochem. J. (1990) 265:871–878.
   PubMedGoogle Scholar
• DE LASZLO SE, BUSH BL, DOYLE .11, GREENLEE WJ, HAN-GAUER DG, HALGREN TA, LYNCH RJ, SCHORN TW, SIEGL PK: Synthesis and use of 3-amino-4-pheny1-2-piperi-dones and 4-amino-2-ben7g7epin-3-ones as conforma-tionally restricted phenylalanine isosteres in renin Inhibitors. J. Med. Chem. (1992) 35:833–846.
   Google Scholar
• MARTIN SF, AUSTIN RE, OALMANN CJ, BAKER WR, CON-DON SL, DE LARA E, ROSENBERG SH, SPINA ICP, STEIN HE, COHEN J: 1,2,3- Trisubstkuted cyclopropanes as confor-mationalty restricted peptide isosteres: application to the design and syntheses of novel renin inhibitors. J. Med. Chem. (1992) 35:1710–1721.
   PubMedGoogle Scholar
• BRADBURY RH, RIVETT JE: 1,2,4-Triazolo(4,3-a)pyrazinederivatives with human renin inhibitory activity. 3. Synthesis and biology of aminodeoary-statine and di-fluorostatone derivatives. J. Med. Chem. (1991) 34:151-157. (see references cites).
   Google Scholar
• BAKER WR, FUNG AK, KLEINERT HD, STEIN HH, PLATTNER JJ, ARMIGER YL, CONDON SL, COHEN J, EGAN DA, BARLOW JL et al.: Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2-P3 amide bond replacement. J. Med. Chem. (1992) 1722–1734.
   PubMedGoogle Scholar
• STEIN HH, FUNG AK, COHEN J, BAKER WR, ROSENBERG SH, BOYD SA, DAYTON BD, ARMIGER YL, CONDON SL, MANTEI RA et al.: Slow, tight binding to human renin in some nonpeptidic renin inhibitors containing a 4-methozymethoxypiperidinylamide at the P4 position. Febs. Lett. (1992) 300:301–304.
   PubMedGoogle Scholar
• KLEINERT HD, STEIN HH, BOYD S, FUNG AK, BAKER WR, VERBURG KM, POLAKOWSKI JS, KOVAR P, BARLOW J, COHEN J et al.: Discovery of a well-absorbed, efficacious renin inhibitor, A- 74273. Hypertension (1992) 20:768–775.
   PubMedGoogle Scholar
• VERBLTRG KM, POLAKOWSKI JS, KOVAR PJ, KLINGHOFER V, BARLOW JL, STEIN HH, MANTI RA, FUNG AKL, BOYD SA, BAKER WR, KLEINERT HD: Effects of high doses of A-74273, a novel nonpeptide and orally bioavailable renin-inhibitor. J. Cardiovasc. Pharmacol. (1993) 21:149–155.
   PubMedGoogle Scholar
• KLEINERT HD, ROSENBERG SH, BAKER WR, STEIN HH, ICLINGHOFER V, BARLOW J, SPINA K, POLAKOWSKI J, KOVAR P, COHEN J et al.: Discovery of a peptide-based renin inhibitor with oral bloavailability and efficacy. Science 1992, 257:1940–1943.
   PubMed Web of Science ®Google Scholar
• OCAIN TD, DEININGER DD, RUSSO R, SENKO NA, KATZ A, KITZEN JM, MITCHELL R, OSHIRE G, RUSSO A, STUPI-ENSKI R etal.: New modified heterocyclic phenylalanine derivatives. Incorporation into potent inhibitors of human renin. J. Med. Chem. (1992) 35:823–832.
   Google Scholar
• GREVEL J: Absorption of cyclosporine A after oral dos-ing. Transplant. Proced. (1986) 18\(supp15):9–15.
   Google Scholar
• WEBER AE, HALGREN TA, DOYLE JJ, LYNCH RJ, SIEGEL PKS, PARSONS WH, GREENLEE WJ, PATCHETT AA: Design and synthesis of P2- Pi' linked macrocyclic human renin Inhibitors. J. Med. Chem. (1991) 34:2692–2701.
   PubMedGoogle Scholar
• RIVERO RA, GREENLEE WJ: The synthesis of novel macro-cyclic inhibitors of human renin. Tetrahedron Lett. (1991) 32:2453–2456.
   Google Scholar
• WeberAE, SteinerMG, Krieter PA, Colletti AE, TataJR, HalgrenTA, Ball RG, Doyle JJ, Schorn 7'W, Stearns RA, Miller RR, Siegl PKS, Gmenk,e WJ, Patchett AA: Highly potent, orally active diester macrocyclic human renin inhibitors. J. Med. Chem. (1992) 35:3755–3773.
   PubMedGoogle Scholar
• ABBOTT LAB, EP–456185–A.
   Google Scholar
• ABBOTT LAB, W09222313–A.
   Google Scholar
• ABBOTT LAB, W09203429-0A.
   Google Scholar
• ABBOTT LAB, W09200972–A.
   Google Scholar
• AMERICAN CYANANMID, US5106835–A.
   Google Scholar
• AMERICAN CYANANMID, US5104869–A.
   Google Scholar
• AMERICAN CYANANMID, EP–473936–A.
   Google Scholar
• AMERICAN HOME PRODUCT CORP, US5095119–A.
   Google Scholar
• AMERICAN HOME PRODUCT CORP, US5075451–A.
   Google Scholar
• BAYER AG, DE4038947–A.
   Google Scholar
• BAYER AG, DE4038921–A.
   Google Scholar
• BAYER AG, EP–489323–A.
   Google Scholar
• BAYER AG, DE4020942–A.
   Google Scholar
• FUJISAWA PHARM CO LTD, W09217456–A.
   Google Scholar
• FUJISAWA PHARM CO LTD, W09215296–A.
   Google Scholar
• FUJISAWA PHARM CO LTD, EP–476515–A.
   Google Scholar
• HOECHST AG, EP–519434.
   Google Scholar
• HOECHST AG, EP–519433.
   Google Scholar
• HOECHST AG, EP512415–A.
   Google Scholar
• HOECHST AG, DE4037437–A.
   Google Scholar
• HOECHST AG, EP483403–A.
   Google Scholar
• HOECHST AG, EP464639–A.
   Google Scholar
• HOFFMANN LA ROCHE, EP–509354–A.
   Google Scholar
• HOFFMANN LA ROCHE, EP–475255–A.
   Google Scholar
• HOFFMANN LA ROCHE, EP–464572–A.
   Google Scholar
• JAPAN TOBACCO INC, W09216497–A.
   Google Scholar
• JAPAN TOBACCO INC, W09213827–A.
   Google Scholar
• MERCK & CO INC, US5169952–A.
   Google Scholar
• MERCK & CO INC, EP-518676–A.
   Google Scholar
• MERCK & CO INC, EP-518675–A.
   Google Scholar
• MERCK & CO INC, EP-518672.
   Google Scholar
• MERCK & CO INC, US5114925–A.
   Google Scholar
• E MERCK PATENT GmbH, EP–501280–A.
   Google Scholar
• E MERCK PATENT GmbH, DE4104024–A.
   Google Scholar
• E MERCK PATENT GmbH, EP–490259–A.
   Google Scholar
• E MERCK PATENT GmbH, EP–481311–A.
   Google Scholar
• E MERCK PATENT GmbH, DE4027457–A.
   Google Scholar
• E MERCK PATENT GmbH, EP–464517–A.
   Google Scholar
• E MERCK PATENT GmbH, EP–456039,
   Google Scholar
• NIPPON KAYAKU KK, JP4208257–A.
   Google Scholar
• NIPPON KAYAKU ICK, JP4193851–A.
   Google Scholar
• PFIZER INC, EP–473337–A.
   Google Scholar
• SAGAMI CHEM RES CENTRE, JP4117270–A.
   Google Scholar
• SAGAMI CHEM RES CENTRE, JP4046174–A.
   Google Scholar
• SANADOZ PATENT GMBH, DE4025879–A.
   Google Scholar
• SHIONOGI KK, EP–468641–A.
   Google Scholar
• SMITHKLINE BEECHAM CORP, W09209297–A.
   Google Scholar
• TAKASAGO INT CORP, EP–470702–A.
   Google Scholar
• TAKASAGO INT CORP, EP–519763–A.
   Google Scholar
• TANABE SEIYAKU CO, EP–519738–A.
   Google Scholar
• TERUMO CORP, JP4202169–A.
   Google Scholar
• UPJOHN CO, EP–486478–A.
   Google Scholar
• UPJOHN CO, W09203472–A.
   Google Scholar
• WARNER LAMBERT CO, US5162527–A.
   Google Scholar
• WARNER LAMBERT CO, US5149692–A.
   Google Scholar
• WARNER LAMBERT CO, US5135914–A.
   Google Scholar
• WARNER LAMBERT CO, US5114937–A.
   Google Scholar
• WARNER LAMBERT CO, US5071837–A.
   Google Scholar
• WARNER LAMBERT CO, US5089616–A.
   Google Scholar
• ALMQUIST R, W09221696–A.
   Google Scholar